EP4602049A1 — Sos1 inhibitors
Assigned to Bayer AG · Expires 2025-08-20 · 1y expired
What this patent protects
The present invention covers phosphinoxide substituted pyrido[3,4-d]pyrimidine compounds of general formula (I) : in which R 1 , R 2 , R 3 and R 4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceuti…
USPTO Abstract
The present invention covers phosphinoxide substituted pyrido[3,4-d]pyrimidine compounds of general formula (I) : in which R 1 , R 2 , R 3 and R 4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
Drugs covered by this patent
- Alunbrig (brigatinib) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.